What Stanza Treats: Main Uses and Benefits

Stanza (Mefenamic Acid) is commonly used to help with symptoms related to physical discomfort, which may include mild to moderate pain. The medicine is applied across domains where additional symptomatic support is needed, focusing primarily on conditions characterized by episodic or fluctuating manifestations.

The primary therapeutic areas may include managing the painful cramping of primary dysmenorrhea and assisting with symptoms related to excessive menstrual flow (menorrhagia). It can also provide support for acute pain associated with injury, dental discomfort, or headaches. Furthermore, it is relevant for easing symptoms that create noticeable physiological strain in chronic conditions like arthritis, and is commonly used for the systemic imbalance of fever.

Quick Fact: Support for Cyclical Discomfort
Primary Focus: Supportive relief for symptoms of intense menstrual cramping and associated discomfort.
Usage Context: Applied during phases when symptoms become more noticeable, often for short-term assistance.

Regulatory References

1. NIH MedlinePlus overview

Stanza is a prescription-only computerized behavioral therapy device, not a chemical drug, that is indicated for the treatment of fibromyalgia symptoms in adult patients. Its use is defined and restricted by formal regulatory classifications established by the U.S. Food and Drug Administration (FDA).

Contraindications and Restrictions

Stanza must not be used by patients for whom the risks clearly outweigh the potential benefits. These formal contraindications are:

• Patients who have severe, untreated depression.
• Patients who are at risk of harming themselves.

Restricted Eligibility and Use:

Classification	Eligible Population Status
Acute Safety Risk	Contraindicated for severe, untreated depression or risk of self-harm.
Required Oversight	Restricted to prescription use; intended as an adjunct to clinician supervised outpatient treatment.
Exclusions/Use Not Established	Individuals with a lifetime history of bipolar or other psychotic disorders, or those already receiving psychotherapy, were excluded from clinical trials.
Age Group	Indicated for adult patients (clinical studies included individuals aged 22 to 75 years).

The device is not a standalone therapy and must be used as part of a patient's overall management plan under the care of a healthcare professional. Eligibility is strictly limited to the adult population with fibromyalgia symptoms.

Interactions with other medicines and products

The interaction profile of Stanza (Mefenamic Acid) is officially documented by regulatory authorities, focusing on specific drug-drug combinations and pharmacokinetic alterations.

Interactions Affecting Drug Exposure

Mefenamic Acid is primarily metabolized by the CYP2C9 enzyme. Co-administration with certain agents results in altered systemic exposure. For example, co-ingestion of Magnesium Hydroxide antacids significantly increases the rate and extent of Mefenamic Acid absorption. Conversely, Mefenamic Acid can decrease the elimination of medicines like Lithium and Methotrexate, leading to higher plasma concentrations of these agents.

Pharmacodynamic and Additive Risks

The combination of Stanza with other agents can result in additive or antagonistic effects. Co-administration with Oral Anticoagulants (e.g., Warfarin) may enhance the anticoagulant effect and increase the risk of bleeding. Stanza can also interfere with the anti-platelet effect of low-dose Aspirin, which is relevant for cardiovascular prophylactic therapy. Concomitant use with Corticosteroids or SSRIs carries an increased risk of serious gastrointestinal events. Furthermore, the medicine is documented to reduce the efficacy of Antihypertensives, including ACE inhibitors and diuretics.

Interaction Restrictions

Specific constraints are placed on use, including the prohibition of the medicine for peri-operative pain in the setting of CABG surgery. Use of alcohol is documented as an additional risk factor for serious gastrointestinal adverse events. For populations with existing vulnerabilities, such as the elderly or those with impaired renal function, co-administration with diuretics or ACE inhibitors carries an increased risk of renal deterioration.

Molecular Blockade of Eicosanoid Synthesis

The primary action of Stanza (Mefenamic Acid) involves the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This mechanism acts early in the Arachidonic Acid Cascade to suppress the creation of prostaglandins, which are key biological mediators in local inflammatory and nociceptive signaling pathways.

Modulation of Nociceptive and Thermoregulatory Pathways

The resulting decrease in prostaglandin levels produces two primary physiological effects. Peripherally, it dampens the process of nociceptor sensitization, which elevates the peripheral nociceptive threshold. Centrally, the mechanism prevents PGE2 synthesis in the hypothalamus, which influences the central hypothalamic set-point for temperature regulation.

Constraints of Non-Selective Enzyme Modulation

Stanza's mechanism is physiologically constrained by its non-selective profile. The concurrent inhibition of COX-1 reduces the formation of prostaglandins involved in homeostatic functions, such as mucosal defense. This functional profile differs from mechanisms that selectively inhibit only the COX-2 enzyme.

How to Use Stanza: Official Administration Guidelines

Stanza (Mefenamic Acid) is administered according to a structured protocol, focusing strictly on the required dosing and timing, not the clinical justification for use. This framework mandates oral administration only, available commercially as capsules or tablets.

Administration Scope

Instruction	Detail
Route of administration	Oral (must be swallowed)
Timing in relation to meals	Must be consumed with food or milk for optimal administration tolerance.

Official Dosing and Duration

The standard protocol involves starting treatment with a 500 mg initial dose, followed by a 250 mg maintenance dose taken every six hours (q6h) as needed. This regimen adheres to the recommended daily use limit, which is typically 1000 mg.

The use of Stanza is strictly time-limited, restricting its application to short symptomatic periods. For acute pain, use must not exceed 7 days. For primary dysmenorrhea, use is typically limited to 2 to 3 days, with administration beginning at the onset of symptoms.

Population-Specific Use Rules

Guidelines address specific population use. For older adults, the lowest effective dose is used for the shortest possible duration. Furthermore, Mefenamic Acid is generally not recommended for use in children under 14 years for the treatment of pain and dysmenorrhea. This duration- and dose-constrained approach defines the entirety of the medicine’s labeled usage pattern.

Stanza: Recent Clinical Evidence

Stanza is a prescription digital therapeutic (PDT) that delivers Acceptance and Commitment Therapy (ACT), a form of Cognitive Behavioral Therapy (CBT), specifically for the management of fibromyalgia symptoms in adults. It is not a drug, but an FDA-cleared device requiring a prescription.

Clinical evidence primarily stems from the pivotal PROSPER-FM Phase 3 trial, a large, multi-center, randomized controlled trial (RCT) published in The Lancet in 2024, involving 275 participants.

---

Efficacy and Outcomes

The RCT compared Stanza (a self-guided, smartphone-based program) to a digital symptom tracker control over 12 weeks. Key findings included:

Measured Outcome	Stanza Group Improvement at 12 Weeks	Control Group Improvement at 12 Weeks
Well-being (Patient Global Impression of Change, PGIC)	70.6% of participants reported improvement	22.2% reported improvement
Fibromyalgia Severity (Revised Fibromyalgia Impact Questionnaire, FIQ-R total score)	Statistically greater improvement than control	Less improvement than Stanza arm

Improvements were also observed across multiple secondary endpoints, including measures of pain intensity, pain interference, fatigue, sleep disturbance, and depression. A follow-up extension study suggested that the benefits gained were maintained up to 12 months in a subset of participants.

---

Safety Profile

Stanza demonstrated a favorable safety profile across the clinical trials. No treatment-related adverse events were observed in the pivotal 12-week RCT.

Common questions about Stanza (FAQ)

Q: Is Stanza the same type of medicine as [similar drug name]?

According to official product information, Stanza contains Mefenamic Acid, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Medicines in this classification share a similar primary mechanism of action by influencing the body's inflammatory response.

Q: Can Stanza be taken by people with kidney problems?

Regulatory documents state that Stanza is not recommended for use in patients with significantly impaired renal function (severe kidney disease). For individuals with existing conditions that affect kidney function, or those taking certain other medicines, closer medical oversight and monitoring are often noted in prescribing information.

Q: Can Stanza be taken by people with liver issues?

Official information indicates that Stanza is contraindicated in patients with severe hepatic impairment (severe liver issues). For those with less severe liver impairment, official labeling often advises caution and notes the importance of monitoring liver function.

Q: Does Stanza interact with birth control pills?

Regulatory-related information indicates that co-administration with combination oral contraceptives containing a specific ingredient called drospirenone (DRSP) may increase the risk of elevated potassium levels in certain individuals. Information on other types of oral contraceptives is not commonly highlighted in regulatory summaries.

Q: Does Stanza have a black box warning?

Yes. Official labeling includes serious warnings about the potential for cardiovascular thrombotic events (such as heart attack and stroke) and serious gastrointestinal events (such as bleeding and ulceration). These warnings are formally designated by the FDA to call attention to serious risks associated with the medicine.

Q: How quickly should I expect Stanza to start working?

Studies and official information indicate that the concentration of the medicine in the blood generally reaches its peak within 2 to 4 hours after administration.

Q: What happens if I forget to take a dose of Stanza?

Regulatory-consistent patient guidance often describes a protocol where a missed dose is taken when remembered, unless it is almost time for the next scheduled dose. The guidance notes that patients should avoid taking double or extra doses.

Q: Is Stanza a controlled substance?

Stanza (Mefenamic Acid) is classified as a prescription-only (Rx) medicine. It is not classified as a controlled substance under the U.S. Controlled Substances Act or similar international frameworks.

Q: Are there long-term side effects associated with Stanza?

Official documents note that the risk of serious side effects, such as cardiovascular thrombotic events and severe GI events, may increase with the duration of use. Because Stanza is approved for short-term use, long-term studies to evaluate for carcinogenic potential have not been conducted.

Q: Can Stanza be used during pregnancy or while breastfeeding?

Pregnancy: Official documents advise that Stanza is generally not recommended at 20 weeks gestation and later due to potential risks to the fetus, and it is contraindicated (is not authorized) during the last trimester (30 weeks and later).

Breastfeeding: Use is not recommended as trace amounts of the medicine are excreted into human milk.

Q: Can Stanza affect sleep?

The adverse reactions documented in regulatory sources include drowsiness as a possible effect. The official information does not commonly cite generalized sleep disturbance or insomnia as frequent or documented adverse events.

Q: What should I do if I think Stanza is not working?

Official guidance is non-directive. If an individual believes a product is not working or is causing a serious reaction, official guidance recommends that individuals communicate this concern to their healthcare provider.

Q: Does Stanza need to be refrigerated?

Official storage requirements state the medicine should be stored at controlled room temperature, typically not exceeding 30°C (86°F). Refrigeration is not specified or required.

Q: Is Stanza a new medicine or has it been around a while?

Stanza, which contains Mefenamic Acid, is an established medicine. It was first approved for use in the United States in 1967 and has been used globally for its approved indications since the 1960s.

Q: Why do official documents mention specific tests are needed before or during Stanza use?

Official prescribing information states that patients on long-term treatment require monitoring of hemoglobin or hematocrit to check for potential anemia. Monitoring of liver function tests is also noted in the documentation.

Q: How is Stanza eliminated from the body?

The medicine is primarily processed (metabolized) by the CYP2C9 enzyme in the liver. It is eliminated from the body by the kidneys (approximately 52% of a dose) and in feces (up to 20% of a dose), mainly in the form of metabolites.

Q: What kind of medical professional is eligible to prescribe Stanza?

Stanza (Mefenamic Acid) is classified as a prescription-only (Rx) medicine. This means it must be prescribed by a healthcare professional who is officially licensed to write prescriptions.

Q: Can I take Stanza if I am fasting?

The official prescribing information states that the medicine should be administered with food or milk. This practice is noted to optimize administration tolerance and reduce the potential for stomach upset.

Q: How long does Stanza stay in your system?

The elimination half-life of the parent drug is approximately 2 to 4 hours. This time period is used by healthcare professionals to estimate how long a substance remains in the body and guide dosage schedules.

Q: What kind of research studies were done on Stanza?

The medicine was studied in controlled clinical trials for its approved uses, including the treatment of acute pain and dysmenorrhea. For example, official labeling references trials that compared the medicine to a placebo for primary dysmenorrhea.

How to Store and Dispose of Stanza

Stanza (Mefenamic Acid) must be stored under specific conditions to ensure its stability and safety, as detailed in official regulatory documentation.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically not exceeding 30°C (86°F).
Environment	Keep the medicine in a cool, dry place and protect it from light.
Container	Store in the original container and keep it tightly closed to avoid exposure to moisture.
Child Safety	It is mandatory to keep Stanza out of the sight and reach of children.

Disposal Instructions

Unused or expired Stanza must be disposed of properly. Do not dispose of the medicine by flushing it down a toilet or pouring it into a drain. The product should be discarded using a formal drug take-back program or by following specific instructions from your pharmacist or local waste regulations for non-flushable medicines.